Literature DB >> 19427634

Increased per cell IFN-gamma productivity indicates recent in vivo activation of T cells.

Tobias R Schlingmann1, Carey L Shive, Oleg S Targoni, Magdalena Tary-Lehmann, Paul V Lehmann.   

Abstract

Immunization with vaccinia virus causes long-term immunity. Efforts have been made to characterize the T cells responsible for this protection. Recently, T cell subsets were described that not only co-express multiple cytokines, but also show increased per cell cytokine productivity. These highly productive cells are often considered to be the most protective. We used ELISPOT assays to measure per cell IFN-gamma productivity of vaccinia-specific T cells in childhood immunized adults immediately before and at different time points after vaccinia re-vaccination. Apart from an increase in frequency, we found a marked increase of IFN-gamma productivity following vaccinia re-vaccination. However, these changes were short-lived as both parameters quickly returned to baseline values within 22days after re-vaccination. Therefore, increased per cell IFN-gamma productivity seems to be a sign of recent in vivo T cell activation rather than a stable marker of a distinct T cell subset responsible for long-term immune protection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19427634      PMCID: PMC2706289          DOI: 10.1016/j.cellimm.2009.04.002

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  33 in total

1.  Cutting edge: long-term B cell memory in humans after smallpox vaccination.

Authors:  Shane Crotty; Phil Felgner; Huw Davies; John Glidewell; Luis Villarreal; Rafi Ahmed
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

2.  Duration of antiviral immunity after smallpox vaccination.

Authors:  Erika Hammarlund; Matthew W Lewis; Scott G Hansen; Lisa I Strelow; Jay A Nelson; Gary J Sexton; Jon M Hanifin; Mark K Slifka
Journal:  Nat Med       Date:  2003-08-17       Impact factor: 53.440

3.  Detection of low-frequency antigen-specific IL-10-producing CD4(+) T cells via ELISPOT in PBMC: cognate vs. nonspecific production of the cytokine.

Authors:  Robert E M Guerkov; Oleg S Targoni; Christian R Kreher; Bernhard O Boehm; Maria T Herrera; Magdalena Tary-Lehmann; Paul V Lehmann; Stephan K Schwander
Journal:  J Immunol Methods       Date:  2003-08       Impact factor: 2.303

4.  The secretory IFN-gamma response of single CD4 memory cells after activation on different antigen presenting cell types.

Authors:  Patrick A Ott; Magdalena Tary-Lehmann; Paul V Lehmann
Journal:  Clin Immunol       Date:  2007-07-13       Impact factor: 3.969

5.  Direct visualization of cytokine-producing recall antigen-specific CD4 memory T cells in healthy individuals and HIV patients.

Authors:  T Helms; B O Boehm; R J Asaad; R P Trezza; P V Lehmann; M Tary-Lehmann
Journal:  J Immunol       Date:  2000-04-01       Impact factor: 5.422

6.  Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines.

Authors:  Ingo Drexler; Caroline Staib; Wolfgang Kastenmuller; Stefan Stevanović; Burkhard Schmidt; François A Lemonnier; Hans-Georg Rammensee; Dirk H Busch; Helga Bernhard; Volker Erfle; Gerd Sutter
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-23       Impact factor: 11.205

7.  Response to smallpox vaccine in persons immunized in the distant past.

Authors:  Sharon E Frey; Frances K Newman; Lihan Yan; Kathleen R Lottenbach; Robert B Belshe
Journal:  JAMA       Date:  2003-06-25       Impact factor: 56.272

8.  Quantitation of CD8+ T cell responses to newly identified HLA-A*0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses.

Authors:  Masanori Terajima; John Cruz; Gregory Raines; Elizabeth D Kilpatrick; Jeffrey S Kennedy; Alan L Rothman; Francis A Ennis
Journal:  J Exp Med       Date:  2003-03-31       Impact factor: 14.307

9.  Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans.

Authors:  Behazine Combadiere; Alexandre Boissonnas; Guislaine Carcelain; Evelyne Lefranc; Assia Samri; François Bricaire; Patrice Debre; Brigitte Autran
Journal:  J Exp Med       Date:  2004-06-07       Impact factor: 14.307

10.  Cellular and humoral immunity against vaccinia virus infection of mice.

Authors:  Rong Xu; Aaron J Johnson; Denny Liggitt; Michael J Bevan
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

View more
  11 in total

1.  A Whole Blood Enzyme-Linked Immunospot Assay for Functional Immune Endotyping of Septic Patients.

Authors:  Monty B Mazer; Charles C Caldwell; Jodi Hanson; Daniel Mannion; Isaiah R Turnbull; Anne Drewry; Dale Osborne; Andrew Walton; Tessa Blood; Lyle L Moldawer; Scott Brakenridge; Kenneth E Remy; Richard S Hotchkiss
Journal:  J Immunol       Date:  2020-11-25       Impact factor: 5.422

2.  Lesson for the clinical nephrologist: immune monitoring of human JC-polyomavirus in kidney transplantation.

Authors:  Tristan de Nattes; Isabelle Etienne; Emmanuel Gerardin; Dominique Bertrand; Sophie Candon
Journal:  J Nephrol       Date:  2021-09-06       Impact factor: 4.393

3.  Construction and immune protection evaluation of recombinant virus expressing Newcastle disease virus F protein by the largest intergenic region of fowlpox virus NX10.

Authors:  Yan Zhao; Zongxi Han; Xiaocai Zhang; Xuemei Zhang; Junfeng Sun; Deying Ma; Shengwang Liu
Journal:  Virus Genes       Date:  2020-10-03       Impact factor: 2.332

4.  ELISPOTs Produced by CD8 and CD4 Cells Follow Log Normal Size Distribution Permitting Objective Counting.

Authors:  Alexey Y Karulin; Kinga Karacsony; Wenji Zhang; Oleg S Targoni; Ioana Moldovan; Marcus Dittrich; Srividya Sundararaman; Paul V Lehmann
Journal:  Cells       Date:  2015-01-20       Impact factor: 6.600

5.  High Reproducibility of ELISPOT Counts from Nine Different Laboratories.

Authors:  Srividya Sundararaman; Alexey Y Karulin; Tameem Ansari; Nadine BenHamouda; Judith Gottwein; Sreenivas Laxmanan; Steven M Levine; John T Loffredo; Stephanie McArdle; Christine Neudoerfl; Diana Roen; Karina Silina; Mackenzie Welch; Paul V Lehmann
Journal:  Cells       Date:  2015-01-09       Impact factor: 6.600

6.  Cytomegalovirus (CMV)-Specific Perforin and Granzyme B ELISPOT Assays Detect Reactivation of CMV Infection in Inflammatory Bowel Disease.

Authors:  Tobias M Nowacki; Dominik Bettenworth; Matthias Ross; Jan Heidemann; Paul V Lehmann; Andreas Lügering
Journal:  Cells       Date:  2012-04-23       Impact factor: 6.600

7.  ELISPOT Refinement Using Spot Morphology for Assessing Host Responses to Tuberculosis.

Authors:  Laura S Sibley; Andrew D White; Alice Marriott; Michael J Dennis; Ann Williams; Philip D Marsh; Sally A Sharpe
Journal:  Cells       Date:  2012-03-13       Impact factor: 6.600

8.  Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology.

Authors:  Hideaki Tahara; Marimo Sato; Magdalena Thurin; Ena Wang; Lisa H Butterfield; Mary L Disis; Bernard A Fox; Peter P Lee; Samir N Khleif; Jon M Wigginton; Stefan Ambs; Yasunori Akutsu; Damien Chaussabel; Yuichiro Doki; Oleg Eremin; Wolf Hervé Fridman; Yoshihiko Hirohashi; Kohzoh Imai; James Jacobson; Masahisa Jinushi; Akira Kanamoto; Mohammed Kashani-Sabet; Kazunori Kato; Yutaka Kawakami; John M Kirkwood; Thomas O Kleen; Paul V Lehmann; Lance Liotta; Michael T Lotze; Michele Maio; Anatoli Malyguine; Giuseppe Masucci; Hisahiro Matsubara; Shawmarie Mayrand-Chung; Kiminori Nakamura; Hiroyoshi Nishikawa; A Karolina Palucka; Emanuel F Petricoin; Zoltan Pos; Antoni Ribas; Licia Rivoltini; Noriyuki Sato; Hiroshi Shiku; Craig L Slingluff; Howard Streicher; David F Stroncek; Hiroya Takeuchi; Minoru Toyota; Hisashi Wada; Xifeng Wu; Julia Wulfkuhle; Tomonori Yaguchi; Benjamin Zeskind; Yingdong Zhao; Mai-Britt Zocca; Francesco M Marincola
Journal:  J Transl Med       Date:  2009-06-17       Impact factor: 5.531

9.  Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity Responses.

Authors:  Sharon E Frey; Jack T Stapleton; Zuhair K Ballas; Wendy L Rasmussen; Thomas M Kaufman; Tammy P Blevins; Travis L Jensen; D Huw Davies; Magdalena Tary-Lehmann; Paul Chaplin; Heather Hill; Johannes B Goll
Journal:  J Infect Dis       Date:  2021-10-28       Impact factor: 7.759

10.  Memory T cell proliferative responses and IFN-γ productivity sustain long-lasting efficacy of a Cap-based PCV2 vaccine upon PCV2 natural infection and associated disease.

Authors:  Luca Ferrari; Paolo Borghetti; Elena De Angelis; Paolo Martelli
Journal:  Vet Res       Date:  2014-04-16       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.